Akiyama, K (1999) Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophrenia Research 37, 97–106.
Anders, S, Tanaka, M and Kinney, DK (2013) Depression as an evolutionary strategy for defense against infection. Brain, Behavior, and Immunity 31, 9–22.
Borovcanin, M, Jovanovic, I, Radosavljevic, G, Djukic Dejanovic, S, Bankovic, D, Arsenijevic, N et al. (2012) Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. Journal of Psychiatric Research 46, 1421–1426.
Braw, Y, Aviram, S, Bloch, Y and Levkovitz, Y (2011) The effect of age on frontal lobe related cognitive functions of unmedicated depressed patients. Journal of Affective Disorders 129, 342–347.
Camp, NJ, Lowry, MR, Richards, RL, Plenk, AM, Carter, C, Hensel, CH et al. (2005) Genome-wide linkage analyses of extended Utah pedigrees identifies loci that influence recurrent, early-onset major depression and anxiety disorders. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 135B, 85–93.
Capuron, L, Gumnick, JF, Musselman, DL, Lawson, DH, Reemsnyder, A, Nemeroff, CB et al. (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26, 643–652.
Capuron, L and Miller, AH (2011) Immune system to brain signaling: neuropsychoharmacological implications. Pharmacology & Therapeutics 130, 226–238.
Chocano-Bedoya, PO, Mirzaei, F, O'Reilly, EJ, Lucas, M, Okereke, OI, Hu, FB et al. (2014) C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression. Journal of Affective Disorders 163, 25–32.
Cotrena, C, Branco, LD, Shansis, FM and Fonseca, RP (2016) Executive function impairments in depression and biopolar disorder: association with functional impairment and quality of life. Journal of Affective Disorders 190, 744–753.
Coull, JT, Frith, CD, Frackowiak, RS and Grasby, PM (1996) A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia 34, 1085–1095.
Dahl, J, Ormstad, H, Aass, HC, Malt, UF, Bendz, LT, Sandvik, L et al. (2014) The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocriology 45, 77–86.
Danese, A, Moffitt, TE, Pariante, CM, Ambler, A, Poulton, R and Caspi, A (2008) Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Archives of General Psychiatry 65, 409–416.
Dantzer, R, O'Connor, JC, Freund, GG, Johnson, RW and Kelly, KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 9, 46–56.
Di Nicola, M, Cattaneo, A, Hepgul, N, Di Forti, M, Aitchison, KJ, Janiri, L et al. (2012) Serum and gene expression profile of cytokines in first-episode psychosis. Brain, Behavior, and Immunity 31, 90–95.
Dowlati, Y, Herrmann, N, Swardfager, W, Liu, H, Sham, L, Reim, EK et al. (2010) A meta-analysis of cytokines in major depression. Biological Psychiatry 67, 446–457.
Duivis, HE, de Jonge, P, Penninx, BW, Na, BY, Cohen, BE and Whooley, MA (2011) Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. American Journal of Psychiatry 168, 913–920.
Felger, JC and Lotrich, FE (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246, 199–229.
Frydecka, D, Misiak, B, Pawlak-Adamska, E, Karabon, L, Tomkiewicz, A, Sedlaczek, P et al. (2015) Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation. European Archives of Psychiatry and Clinical Neuroscience 265, 449–459.
Ganguli, R, Yang, Z, Shurin, G, Chengappa, KN, Brar, JS, Gubbi, AV et al. (1994) Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Research 51, 1–10.
Gimeno, D, Kivimäki, M, Brunner, EJ, Elovainio, M, De Vogli, R, Steptoe, A et al. (2009) Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychological Medicine 39, 413–423.
Gimeno, D, Marmot, MG and Singh-Manoux, A (2008) Inflammatory markers and cognitive function in middle-aged adults: the White-hall II study. Psychoneuroendocrinology 33, 1322–1334.
Goldsmith, DR, Rapaport, MH and Miller, BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Molecular Psychiatry 21, 1696–1709.
Goodyer, IM (2015) Genes, environments and depression in young people. Archives of Disease in Childhood 100, 1064–1069.
Góra-Gebka, M, Liberek, A, Szydlowska-Lysiak, W, Bako, W and Korzon, M (2003) Serum interleukin 6 and interleukin 12 levels in children with chronic hepatitis HBV treated with interferon alpha. Annals of Hepatology 2, 92–97.
Grassi-Oliveira, R, Bauer, ME, Pezzi, JC, Teixeira, AL and Brietzke, E (2011) Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuroendocrinology Letters 32, 540–544.
Heringa, SM, van den Berg, E, Reijmer, YD, Nijpels, G, Stehouwer, CD, Schalkwijk, CG et al. (2014) Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population-the Hoorn Study. Psychoneuroendocrinology 40, 108–118.
Hiles, SA, Baker, AL, de Malmanche, T and Attia, J (2012) Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychological Medicine 42, 2015–2026.
Howren, MB, Lamkin, DM and Suls, J (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine 71, 171–186.
Jansen, R, Penninx, BW, Madar, V, Xia, K, Milaneschi, Y, Hottenga, JJ et al. (2016) Gene expression in major depressive disorder. Molecular Psychiatry 21, 444.
Jordanova, V, Stewart, R, Davies, E, Sherwood, R and Prince, M (2007) Markers of inflammation and cognitive decline in an African-Caribbean population. International Journal of Geriatric Psychiatry 22, 966–973.
Jung, J, Kang, J, Won, E, Nam, K, Lee, MS, Tae, WS et al. (2014) Impact of lingual gyrus volume on antidepressant response and neurocognitive functions in major depressive disorder: a voxel-based morphometry study. Journal of Affective Disorders 169, 179–187.
Kemp, AH, Hopkinson, PJ, Hermens, DF, Rowe, DL, Sumich, AL, Clark, CR et al. (2009) Fronto-temporal alterations within the first 200 ms during an attentional task distinguish major depression, non-clinical participants with depressed mood and healthy controls: a potential biomarker? Human Brain Mapping 30, 602–614.
Kern, S, Skoog, I, Bőrjesson-Hanson, A, Blennow, K, Zetterberg, H, Ostling, S et al. (2014) Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain, Behavior, and Immunity 41, 55–58.
Khandaker, GM, Stochl, J, Zammit, S, Goodyer, I, Lewis, G and Jones, PB (2017) Childhood inflammatory markers and intelligence as predictors of subsequent persistent depressive symptoms: a longitudinal cohort study. Psychological Medicine 15, 1–12.
Kiecolt-Glaser, JK, Preacher, KL, MacCallum, RC, Atkinson, C, Malarkey, WB and Glaser, R (2003) Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proceedings of the National Academy of Sciences of the United States of America 100, 9090–9095.
Kopf, M, Baumann, H, Freer, G, Freudenberg, M, Lamers, M, Kishimoto, T et al. (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368, 339–342.
Kouwenhoven, M, Ozenci, V, Teleshova, N, Hussein, Y, Huang, YM, Eusebio, A et al. (2001) Enzyme-linked immunospot assays provide a sensitive tool for detection of cytokine secretion by monocytes. Clinical and Diagnostic Laboratory Immunology 8, 1248–1257.
Lee, RS, Hermens, DF, Porter, MA and Redoblado-Hodge, MA (2012) A meta-analysis of cognitive deficits in first-episode major depressive disorder. Journal of Affective Disorders 140, 113–124.
Lekander, M, von Essen, J, Schultzberg, M, Andreasson, AN, Garlind, A, Hansson, LO et al. (2011) Cytokines and memory across the mature life span of women. Scandinavian Journal of Psychology 52, 229–235.
Lezak, MD (1982) The problem of assessing executive functions. International Journal of Psychology 17, 281–297.
Li, CT, Lin, CP, Chou, KH, Chen, IY, Hsieh, JC, Wu, CL et al. (2010) Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. NeuroImage 50, 347–356.
Liu, Y, Ho, RC and Mak, A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. Journal of Affective Disorders 139, 230–239.
Loddick, SA, Turnbull, AV and Rothwell, NJ (1998) Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism 18, 176–179.
Maalouf, FT, Brent, D, Clark, L, Tavitian, L, McHugh, RM, Sahakian, BJ et al. (2011) Neurocognitive impairment in adolescent major depressive disorder: State vs. Trait illness markers. Journal of Affective Disorders 133, 625–632.
Mann, DT, Williams, AM, Ward, P and Janelle, CM (2007) Perceptual-cognitive expertise in sport: a meta-analysis. Journal of Sport & Exercise Psychology 29, 457–478.
Marioni, RE, Strachan, MW, Reynolds, RW, Lowe, GD, Mitchell, RJ, Fowkes, FG et al. (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes 59, 710–713.
Marsland, AL, Petersen, KL, Sathanoori, R, Muldoon, MF, Neumann, SA, Ryan, C et al. (2006) Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosomatic Medicine 68, 895–903.
Mesulam, MM (1985) Principles of Behavioral Neurology. Philadelphia: Davis.
McDermott, LM and Ebmeier, KP (2009) A meta-analysis of depression severity and cognitive function. Journal of Affective Disorders 119, 1–8.
Milaneschi, Y, Corsi, AM, Penninx, BW, Bandinelli, S, Guralnik, JM and Ferrucci, L (2009) Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biological Psychiatry 65, 973–978.
Miller, AH, Maletic, V and Raison, CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 65, 732–741.
Mooijaart, SP, Sattar, N, Trompet, S, Lucke, J, Stott, DJ, Ford, I et al. (2013) Circulating interleukin-6 concentration and cognitive decline in old age: the PROSPER study. Journal of Internal Medicine 274, 77–85.
Noto, C, Maes, M, Ota, VK, Teixeira, AL, Bressan, RA, Gadelha, A et al. (2015) High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World Journal of Biological Psychiatry 27, 1–8.
Paelecke-Habermann, Y, Pohl, J and Leplow, B (2005) Attention and executive functions in remitted major depression patients. Journal of Affective Disorders 89, 125–135.
Paradiso, S, Lamberty, GJ, Garvey, MJ and Robinson, RG (1997) Cognitive impairment in the euthymic phase of chronic unipolar depression. Journal of Nervous and Mental Disease 185, 748–754.
Philips, MR, Zhang, J, Shi, Q, Song, Z, Ding, Z, Pang, S et al. (2009) Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–2005: an epidemiological survey. Lancet 373, 2041–2053.
Porter, RJ, Gallagher, P, Thompson, JM and Young, AH (2003) Neurocognitive impairment in drug-free patients with major depressive disorder. British Journal of Psychiatry 182, 214–220.
Rafnsson, SB, Deary, IJ, Smith, FB, Whiteman, MC, Rumley, A, Lowe, GD et al. (2007) Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. Journal of The American Geriatrics Society 55, 700–707.
Raison, CL, Rutherford, RE, Woolwine, BJ, Shuo, C, Schettler, P, Drake, DF et al. (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 31–41.
Rock, PL, Roiser, JP, Riedel, WJ and Blackwell, AD (2014) Cognitive impairment in depression: a systematic review and meta-analysis. Psychological Medicine 44, 2029–2040.
Sahakian, BJ and Owen, AM (1992) Computerized assessment in neuropsychiatry using CANTAB: discussion paper. Journal of The Royal Society Medicine 85, 399–402.
Setiawan, E, Wilson, AA, Mizrahi, R, Rusjan, PM, Miler, L, Rajkowska, G et al. (2015) Role of translocator protein density: a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72, 268–275.
Shao, TN, Yin, GZ, Yin, XL, Wu, JQ, Du, XD, Zhu, HL et al. (2017) Elevated triglyceride levels are associated with cognitive impairments among patients with major depressive disorder. Comprehensive Psychiatry 75, 103–109.
Simpson, EE, Hodkinson, CF, Maylor, EA, McCormack, JM, Rae, G, Strain, S et al. (2013) Intracellular cytokine production and cognition in healthy older adults. Psychoneuroendocrinology 38, 2196–2208.
Stewart, JC, Rand, KL, Muldoon, MF and Kamarck, TW (2009) A prospective evaluation of the directionality of the depression-inflammation relationship. Brain, Behavior, and Immunity 23, 936–944.
Tartter, M, Hammen, C, Bower, JE, Brennan, PA and Cole, S (2015) Effects of chronic interpersonal stress exposure on depressive symptoms are moderated by genetic variation at IL6 and IL1beta in youth. Brain, Behavior, and Immunity 46, 104–111.
Udina, M, Moreno-España, J, Navinés, D, Giménez, Z, Langohr, K, Gratacòs, M et al. (2013) Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms. Psychoneuroendocrinology 38, 1803–1813.
Upthegrove, R, Manzanares-Teson, N and Barnes, NM (2014) Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophrenia Research 155, 101–108.
van den Biggelaar, AH, Gussekloo, J, de Craen, AJ, Frölich, M, Stek, ML, van der Mast, RC et al. (2007) Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Experimental Gerontology 42, 693–701.
van den Kommer, TN, Dik, MG, Comijs, HC, Jonker, C and Deeg, DJ (2010) Homocysteine and inflammation: predictors of cognitive decline in older persons? Neurobiology of Aging 31, 1700–1709.
van der Meere, J, Börger, N and van Os, T (2007) Sustained attention in major unipolar depression. Perceptual and Motor Skills 104, 1350–1354.
Wang, W, Bian, Q, Zhao, Y, Li, X, Wang, W, Du, J et al. (2014) Reliability and validity of the Chinese version of the Patients Health Questionaire (PHQ-9) in the general population. General Hospital Psychiatry 36, 539–544.
Williams, RA, Hagerty, BM, Cimprich, B, Therrien, B, Bay, E and Oe, H (2000) Changes in directed attention and short-term memory in depression. Journal of Psychiatric Research 34, 227–238.
Wright, CB, Sacco, RL, Rundek, T, Delman, J, Rabbani, L and Elkind, M (2006) Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. Journal of Stroke & Cerebrovascular Diseases 15, 34–38.
Yang, X, Ma, X, Huang, B, Sun, G, Zhao, L, Lin, D et al. (2015) Gray matter volume abnormalities were associated with sustained attention in unmedicated major depression. Comprehensive Psychiatry 63, 71–79.
Yi, Z, Li, Z, Yu, S, Yuan, C, Hong, W, Wang, Z et al. (2012) Blood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder. PLoS ONE 7, e31283.
Zhang, C, Wu, Z, Zhao, G, Wang, F and Fang, Y (2016) Identification of IL6 as a susceptibility gene for major depressive disorder. Scientific Reports 6, 31264.